Bioactive Products
| A unique collection of 184 natural compounds used for Antibacterial research. | ||
| Catalog No: | Bb192 | Antibacterial Compound Library Screening Details |
| Size: | 1mg/well * 184 Compounds 2mg/well * 184 Compounds | |
| Cat. No. | Information |
| CFN93254 | Lysicamine Lysicamine shows significant antioxidant capacity in the ORAC(FL) assay and it is active against S. epidermidis and C. dubliniensis, with MIC values in the range 12.5-100 microg mL(-1). Lysicamine has antimicrobial and anti-inflammation activity, the minimum inhibitory concentrations of the pour component (Streptococcus mutans, Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Candida albicans.) is less than 5mg/ml for all four microorganisms and the minimum concentration with anti-inflammation is 0.2mg/ml for both IL-8 and IL-6. Lysicamine has antileishmanial activity. It can significantly inhibit the proliferation of melanoma cells, it has antioxidative activity and chemopreventive activity in skin melanoma cells. |
| CFN90861 | Continentalic acid Continentalic acid and kaurenoic acid are quality control markers in Aralia continentalis. Continentalic acid has anti-inflammatory, anti-cancer, and anti-bacterial activities, it shows moderate cytotoxicity against A-549 (lung), THP-1 (leukemia) and MCF-7 (breast) cell lines; it has minimum inhibitory concentrations (MICs) of approximately 8-16 microg/mL against S. aureus, including the MSSA and MRSA standard strains. |
| CFN94487 | 7-Hydroxyflavanone 7-Hydroxyflavanone shows antimicrobial activity against Streptococcus pneumoniae clinical isolates, it could be useful for the development of a novel respiratory infections treatment. |
| CFN94405 | 7-Methoxy-4-methylcoumarin 7-Methoxy-4-methylcoumarin is a coumarin derivative and fluorescent label, it displays good activity against B. subtilis. |
| CFN94427 | Vulpic acid Vulpic acid has therapeutic and prophylactic potential to be antibacterial and antiplasmodial agents, it can inhibit one or more enzymes (PfFabI, PfFabG, and PfFabZ) from the plasmodial fatty acid biosynthesis (FAS-II) pathway, a potential drug target for liver stage activity. |
